4.01
price up icon4.16%   0.16
after-market Dopo l'orario di chiusura: 4.02 0.010 +0.25%
loading
Precedente Chiudi:
$3.85
Aprire:
$3.89
Volume 24 ore:
1.67M
Relative Volume:
0.36
Capitalizzazione di mercato:
$1.05B
Reddito:
$194.75M
Utile/perdita netta:
$-51.26M
Rapporto P/E:
-14.32
EPS:
-0.28
Flusso di cassa netto:
$-23.38M
1 W Prestazione:
+2.82%
1M Prestazione:
+10.16%
6M Prestazione:
+67.78%
1 anno Prestazione:
+174.66%
Intervallo 1D:
Value
$3.88
$4.02
Intervallo di 1 settimana:
Value
$3.77
$4.04
Portata 52W:
Value
$1.07
$4.0787

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name
Nome
Akebia Therapeutics Inc
Name
Telefono
617-871-2098
Name
Indirizzo
245 FIRST STREET, CAMBRIDGE, MA
Name
Dipendente
181
Name
Cinguettio
@akebiatx
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
AKBA's Discussions on Twitter

Confronta AKBA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
AKBA
Akebia Therapeutics Inc
4.01 1.01B 194.75M -51.26M -23.38M -0.28
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
153.45 67.31B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.74 45.95B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.75 43.35B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.58 18.68B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
305.61 13.44B 2.99B 1.21B 1.13B 25.06

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-06-04 Ripresa H.C. Wainwright Buy
2025-04-28 Iniziato Leerink Partners Outperform
2025-04-01 Iniziato Jefferies Buy
2023-11-29 Ripresa BTIG Research Buy
2023-08-28 Aggiornamento H.C. Wainwright Neutral → Buy
2023-05-31 Aggiornamento Piper Sandler Neutral → Overweight
2022-03-31 Downgrade H.C. Wainwright Buy → Neutral
2022-03-31 Downgrade Mizuho Buy → Neutral
2022-03-31 Downgrade Needham Buy → Hold
2022-03-31 Downgrade Piper Sandler Overweight → Neutral
2021-03-08 Iniziato Cantor Fitzgerald Overweight
2021-01-29 Downgrade JP Morgan Neutral → Underweight
2019-11-14 Reiterato Needham Buy
2019-08-06 Reiterato H.C. Wainwright Buy
2019-07-11 Reiterato H.C. Wainwright Buy
2019-05-02 Iniziato JP Morgan Overweight
2019-03-20 Iniziato Citigroup Neutral
2018-09-07 Ripresa Morgan Stanley Equal-Weight
2018-08-10 Reiterato Needham Buy
2018-06-06 Reiterato H.C. Wainwright Buy
2017-12-19 Iniziato Piper Jaffray Overweight
2017-12-07 Iniziato BTIG Research Buy
2017-09-15 Iniziato RBC Capital Mkts Sector Perform
2017-07-10 Reiterato H.C. Wainwright Buy
2017-04-27 Reiterato H.C. Wainwright Buy
2017-04-27 Reiterato Needham Buy
2016-12-27 Reiterato H.C. Wainwright Buy
2016-12-20 Reiterato JMP Securities Mkt Outperform
2016-11-15 Iniziato Aegis Capital Buy
2016-09-29 Iniziato Brean Capital Buy
2016-03-16 Reiterato Needham Buy
2016-01-21 Iniziato Credit Suisse Neutral
Mostra tutto

Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie

pulisher
12:14 PM

Is Akebia Therapeutics Inc. a good long term investmentFree Trend-Following Techniques - Autocar Professional

12:14 PM
pulisher
Jul 23, 2025

What analysts say about Akebia Therapeutics Inc. stockFree Consultation - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Akebia Therapeutics Inc. Stock Analysis and ForecastFast-track wealth growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Lobbying Update: $460,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Akebia Therapeutics Inc. stock pricePhenomenal trading returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share - Insider Monkey

Jul 22, 2025
pulisher
Jul 21, 2025

11 Best High Return Penny Stocks to Buy Now - Insider Monkey

Jul 21, 2025
pulisher
Jul 18, 2025

Akebia Therapeutics, Inc. (AKBA) Shareholders Greenlight 18.9 Million Share Increase - MSN

Jul 18, 2025
pulisher
Jul 16, 2025

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of GATO, AKBA and LCID - ACCESS Newswire

Jul 16, 2025
pulisher
Jul 16, 2025

Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

PHD inhibitors reported in Akebia Therapeutics patent - BioWorld MedTech

Jul 16, 2025
pulisher
Jul 14, 2025

Transcript : Akebia Therapeutics, Inc. Presents at H.C. Wainwright 4th Annual Kidney Virtual Conference, Jul-14-2025 10 - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Akebia at H.C. Wainwright: Strategic Insights on Kidney Care Products By Investing.com - Investing.com Canada

Jul 14, 2025
pulisher
Jul 12, 2025

Akebia Ther stock hits 52-week high at 4.08 USD - Investing.com Australia

Jul 12, 2025
pulisher
Jul 11, 2025

Akebia Ther stock hits 52-week high at 4.08 USD By Investing.com - Investing.com Nigeria

Jul 11, 2025
pulisher
Jul 08, 2025

Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT - MSN

Jul 08, 2025
pulisher
Jul 08, 2025

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Upcoming Kidney Disease Conference: Akebia CCO to Share Latest Commercial Strategy - Stock Titan

Jul 08, 2025
pulisher
Jul 07, 2025

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - MSN

Jul 07, 2025
pulisher
Jul 07, 2025

13 Stocks Under $5 With High Upside Potential - Insider Monkey

Jul 07, 2025
pulisher
Jul 03, 2025

Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials - MSN

Jul 03, 2025
pulisher
Jul 01, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 01, 2025
pulisher
Jun 30, 2025

12 Small Cap Stocks with High Upside Potential - Insider Monkey

Jun 30, 2025
pulisher
Jun 27, 2025

Wall Street Nears Record Highs Amid Trade Optimism, Jobs Data, and Fiscal Policies in Focus. - AInvest

Jun 27, 2025
pulisher
Jun 26, 2025

15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey

Jun 26, 2025
pulisher
Jun 23, 2025

Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance

Jun 23, 2025
pulisher
Jun 18, 2025

There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise - simplywall.st

Jun 18, 2025
pulisher
Jun 17, 2025

AVEROA - The Pharma Letter

Jun 17, 2025
pulisher
Jun 16, 2025

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - GlobeNewswire Inc.

Jun 16, 2025

Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$73.31
price up icon 1.34%
$15.02
price up icon 0.60%
$9.37
price up icon 1.41%
drug_manufacturers_specialty_generic RDY
$14.60
price up icon 1.32%
$133.66
price up icon 0.69%
$305.61
price up icon 2.59%
Capitalizzazione:     |  Volume (24 ore):